Sickest cancer patients may get electroporation:
This article was originally published in Clinica
Executive Summary
Genetronics Biomedical has asked the FDA to grant it permission to use its experimental drug delivery technology on patients with aggressive skin, head and neck cancers. The San Diego, California-based company has filed a compassionate use protocol with the agency which would allow it to test its electroporation therapy technique, which uses electric currents to deliver cancer drugs, on patients who have failed standard drug treatment and are not able to, or do not want to, undergo surgery, radiation therapy or additional chemotherapy.